Lenvatinib: established and promising drug for the treatment of advanced hepatocellular carcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Lenvatinib: established and promising drug for the treatment of advanced hepatocellular carcinoma

Published:2021-07-29 Issue:11 Volume:14 Page:1353-1365
ISSN:1751-2433
Container-title:Expert Review of Clinical Pharmacology
language:en
Short-container-title:Expert Review of Clinical Pharmacology

Author:

Catalano Martina¹,Casadei-Gardini Andrea²,Vannini Gianmarco¹,Campani Claudia³,Marra Fabio³⁴,Mini Enrico⁵,Roviello Giandomenico⁵

Affiliation:

1. School of Human Health Sciences, University of Florence, Florence, Italy

2. Department of Medical Oncology, Università Vita-Salute, San Raffaele Hospital IRCCS, Milan, Italy

3. Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy

4. Excellence Center for Research, Transfer snd High Education DenoTHE, Florence, Italy

5. Department of Health Sciences, University of Florence, Florence, Italy

Funder

funded

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/17512433.2021.1958674

Reference126 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level

3. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

4. Nonalcoholic Fatty Liver Disease

5. Hepatocellular carcinoma

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Strategies and Recent Advances on Improving Efficient Antitumor of Lenvatinib Based on Nanoparticle Delivery System;International Journal of Nanomedicine;2024-06

2. Association of serum AFP trajectories and hepatocellular carcinoma outcomes after hepatic arterial infusion chemotherapy: A longitudinal, multicenter study;Cancer Medicine;2024-05-31

3. The immune response of hepatocellular carcinoma after locoregional and systemic therapies: The available combination option for immunotherapy;BioScience Trends;2023-12-31

4. Comparing the efficacy of five first-line treatment regimens for unresectable hepatocellular carcinoma: A network meta-analysis of randomized controlled trials;2023-04-25

5. Cyclopeptide-based Anti-liver Cancer Agents: A Mini-review;Protein & Peptide Letters;2023-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3